Our novel data indicated that HOXA5 acted as a tumor suppressor to inhibit the growth of ECCA by up-regulating MXD1 and p53 expression and HOXA5/MXD1 may be new therapeutic targets for intervention of ECCA. This evidence concerns the gene TP53 and neoplasm.